Rationale and design of ENDEAVOR: a sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Lars H Lund,Carolyn S P Lam, Patricia E Pizzato,Anders Gabrielsen,Erik Michaëlsson,Karin Nelander,Hans Ericsson, Julie Holden, Folke Folkvaljon,Andrea Mattsson,Anna Collén, Malin Aurell,Carl Whatling,Stephan Baldus, Grzegorz Drelich,Assen Goudev,Béla Merkely,Niklas Bergh,Sanjiv J Shah

European journal of heart failure（2023）

引用 3|浏览5

暂无评分

摘要

ENDEAVOR is the first phase 2b-3 study to evaluate whether myeloperoxidase inhibition can improve symptoms and exercise capacity in patients with HFpEF/HFmrEF. Clincaltrials.gov: NCT04986202 This article is protected by copyright. All rights reserved.

查看译文

关键词

Heart failure, Preserved ejection fraction, Mildly reduced ejection fraction, Myeloperoxidase, Inflammation, Randomized controlled trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要